Fri. 15 Mar 2024, 7:02am ET
Benzinga
Biotech, News, Health Care, General
The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg.